{
  "list": [
    {
      "id": "chads2-score-for-atrial-fibrillation",
      "title": "CHADS2 Score for Atrial Fibrillation"
    },
    {
      "id": "curb-65-pneumonia-severity-score",
      "title": "CURB-65 Pneumonia Severity Score"
    }
  ],
  "calculators": [
    {
      "id": "chads2-score-for-atrial-fibrillation",
      "title": "CHADS2 Score for Atrial Fibrillation",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "type": "radio",
          "group": "Congestive Heart Failure History",
          "options": "no/yes",
          "points": "0/1"
        },
        {
          "type": "radio",
          "group": "Hypertension history",
          "options": "no/yes",
          "points": "0/1"
        },
        {
          "type": "radio",
          "group": "Age â‰¥ 75 years",
          "options": "no/yes",
          "points": "0/1"
        },
        {
          "type": "radio",
          "group": "Diabetes melitus history",
          "options": "no/yes",
          "points": "0/1"
        },
        {
          "type": "radio",
          "group": "Stroke or TIA symptoms previously",
          "options": "no/yes",
          "points": "0/2"
        }
      ],
      "results": {
        "0": [
          "Low risk of thromboembolic event. 1.9% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "1": [
          "Intermediate risk of thromboembolic event. 2.8% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "2": [
          "Intermediate risk of thromboembolic event. 4.0% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "3": [
          "High risk of thromboembolic event. 5.9% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "4": [
          "High risk of thromboembolic event. 8.5% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "5": [
          "Note: While history of stroke provides 2 points, most physicians would move these patients directly to the high risk group (>8.5% risk of event per year if no coumadin.)",
          "By points directly: High risk of thromboembolic event. 12.5% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "6": [
          "Note: While history of stroke provides 2 points, most physicians would move these patients directly to the high risk group (>8.5% risk of event per year if no coumadin.)",
          "By points directly: High risk of thromboembolic event. 18.2% risk of event per year if no coumadin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Estimates stroke risk in patients with atrial fibrillation",
          "The CHADS2 score is one of several risk stratification schemes that can help determine the 1 year risk of an ischemic stroke in a non-anticoagulated patient with non-valvular atrial fibrillation and determine which antithrombotic therapy is most appropriate",
          "The CHA2-DS2-VASC score may be a better tool to assess stroke risk in patients with atrial fibrillation.  It risk stratifies these patients better than the CHADS2 score"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Gage BF, Waterman AD, Shannon W, et. al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.",
          "Go AS, Hylek EM, Chang Y, et. al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA. 2003 Nov 26;290(20):2685-92."
        ]
      }
    },
    {
      "id": "curb-65-pneumonia-severity-score",
      "title": "CURB-65 Pneumonia Severity Score",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "type": "checkbox",
          "label": "Confusion (abbreviated Mental Test Score <=8)",
          "points": "1"
        },
        {
          "type": "checkbox",
          "label": "Urea (BUN > 19 mg/dL or 7 mmol/L)",
          "points": "1"
        },
        {
          "type": "checkbox",
          "label": "Respiratory Rate > 30 per minute",
          "points": "1"
        },
        {
          "type": "checkbox",
          "label": "Blood Pressure: diastolic < 60 or systeolic < 90 mmHg",
          "points": "1"
        },
        {
          "type": "checkbox",
          "label": "Age >= 65 years",
          "points": "1"
        }
      ],
      "results": {
        "0": [
          "Low risk group: 0.6% 30-day mortality.",
          "Consider outpatient treatment."
        ],
        "1": [
          "Low risk group: 2.7% 30-day mortality.",
          "Consider outpatient treatment."
        ],
        "2": [
          "Moderate risk group: 6.8% 30-day mortality.",
          "Consider inpatient treatment or outpatient with close followup."
        ],
        "3": [
          "Severe risk group: 14.0% 30-day mortality.",
          "Consider inpatient treatment with possible intensive care admission."
        ],
        "4": [
          "Highest risk group: 27.8% 30-day mortality.",
          "Consider inpatient treatment with possible intensive care admission."
        ],
        "5": [
          "Highest risk group: 27.8% 30-day mortality.",
          "Consider inpatient treatment with possible intensive care admission."
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "CURB-65 estimates the mortality of community-acquired pneumonia to help determine inpatient vs outpatient treatment",
          "Compared to the Pneumonia Severity Index (PSI), CURB-65 offers equal sensitivity of mortality prediction due to community-acquired pneumonia.  In fact, CURB-65 has a higher specificity than PSI"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Lim WS, van der Eerden MM, Laing R, et. al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377-82.",
          "Lim WS, Macfarlane JT, Boswell TC, et. al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001 Apr;56(4):296-301."
        ]
      }
    }
  ]
}
